¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"molecular tumor markers"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾¾ç
  • Gleason tumor grade
    ±Û¸®½¼Á¾¾çµî±Þ
  • glomus tumor
    Å丮Á¾¾ç, »ç±¸Á¾¾ç
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
  • granulosa-theca cell tumor
    °ú¸³³­Æ÷¸·¼¼Æ÷Á¾¾ç
  • homologous tumor
    µ¿Á¾Á¾¾ç
  • juxtaglomerular cell tumor
    Å丮°ç¼¼Æ÷Á¾¾ç, »ç±¸Ã¼¿·¼¼Æ÷Á¾¾ç
  • Krukenberg¡¯s tumor
    Å©·çÄ˹ö±×Á¾¾ç
  • Leydig cell tumor
    ¶óÀ̵ðÈ÷¼¼Æ÷Á¾¾ç
  • mixed germ cell tumor
    È¥ÇÕÁ¾ÀÚ¼¼Æ÷Á¾¾ç
  • mixed tumor
    È¥ÇÕÁ¾¾ç
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • melanotic neuroectodermal tumor
    ¸á¶ó´Ñ½Å°æ¿Ü¹è¿±Á¾¾ç, Èæ»ö½Å°æ¿Ü¹è¿±¼ºÁ¾¾ç
  • mesenchymal tumor
    Áß°£¿±Á¾¾ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • desmoid tumor
    µ¥½º¸ðÀ̵åÁ¾¾ç
  • tumor embolism
    Á¾¾ç»öÀüÁõ
  • fecal tumor
    (¢¡stercoroma) ´ëº¯µ¢ÀÌ
  • tumor angiogenesis factor
    Á¾¾çÇ÷°üÇü¼ºÀÎÀÚ
  • tumor necrosis factor
    Á¾¾ç±«»çÀÎÀÚ
  • genitourinary tumor
    ºñ´¢»ý½ÄÁ¾¾ç
  • glomus tumor
    Å丮Á¾¾ç, »ç±¸Á¾¾ç
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • gross tumor volume
    ¸Ç´«Á¾¾çüÀû
  • tumor suppressor gene
    Á¾¾ç¾ïÁ¦À¯ÀüÀÚ
  • heterogenous tumor
    ÀÌÁúÁ¾¾ç
  • homologous tumor
    µ¿Á¾Á¾¾ç
  • hormone dependent tumor
    È£¸£¸óÀÇÁ¸Á¾¾ç
  • infiltrating tumor
    ħÀ±Á¾¾ç
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • hypothalamus,suprasellar tumor
    ¾È»óÁ¾¾ç
  • ileocecal tumor
    ȸ¸ÍºÎÁ¾¾ç.
  • insulin secreting islet cell tumor
    Àν¶¸° ºÐºñ¼º µµ¼¼Æ÷Á¾¾ç.
  • phyllodes tumor
    ¿±»óÁ¾¾ç(ç¨ßÒðþåË)
  • pineal tumor
    ¼Û°úüÁ¾¾ç(¡­ðþåË).
  • pineal tumor
    ¼Û°úüÁ¾¾ç(áæÍýô÷ðþåË)
  • pituitary tumor
    ÇϼöüÁ¾¾ç(¡­ðþåË).
  • pituitary tumor
    ÇϼöüÁ¾¾ç(ù»á÷ô÷ðþåË)
  • placental site trophoblastic tumor
    ŹݺÎÂøºÎÀ§ À¶¸ð»óÇǼºÁ¾¾ç
  • plasma cell tumor
    ÇüÁú¼¼Æ÷Á¾¾ç
  • polipoid tumor
    Æú¸³¾çÁ¾¾ç(¡­åÆðþåË)
  • posterior fossa tumor
    ÈĵοÍÁ¾¾ç(ýªÔéèÀðþåË)
  • pregnancy tumor
    ÀÓ½ÅÁ¾¾ç(ìõããðþåË)
  • primary tumor
    ¿ø¹ßÁ¾¾ç(ê«Û¡ðþåË)
  • primitive neuroectodermal tumor
    ¿ø½Ã½Å°æ¿Ü¹è¿±Á¾¾ç(ê«ã·ãêÌèèâÛÏç¨ðþåË)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • molecular layer plexiform layer
    ºÐÀÚÃþ
  • molecular lesion
    ºÐÀÚº´º¯(¡­Ü»Ü¨).
  • molecular magnet
    ºÐÀÚÀÚ¼®(¡­í¸à´).
  • molecular marker
    ºÐÀÚÇ¥Áö(ÀÚ)
  • molecular mimicry
  • molecular miocrobiology
    ºÐÀڹ̻ý¹°ÇÐ
  • molecular motion
    ºÐÀڿ(¡­ê¡ÔÑ).
  • molecular orientation
    ºÐÀÚ¹èÇâ(¡­ÛÕú¾).
  • molecular pathology
    ºÐÀÚº´¸®ÇÐ(¡­Ü»ìµùÊ)
  • molecular pharmacology
    ºÐÀھฮÇÐ(¡­å·ìµùÊ).
  • molecular physiology
    ºÐÀÚ»ý¸®ÇÐ (¡­ßæìµùÊ).
  • molecular radiation biology
    ºÐÀÚ¹æ»ç¼±»ý¹°ÇÐ
  • molecular rearrangement
    ºÐÀÚÀç¹è¿­.
  • molecular refraction
    ºÐÀÚ±¼Àý(¡­ÏÝï¹).
  • molecular shape
    ºÐÀÚÇü»ó(¡­û¡ßÒ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
TSA technical surgical assistance; toluene sulfonic acid; total shoulder arthroplasty; total solute abso...
TSTA toxoplasmin skin test antigen; tumor-specific tissue antigen; tumor-specific transplantation antigen...
HMW High Molecular Weight
HMWM High Molecular Weight Multimers
MW Molecular Weight
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
LMW-BCGF Low-molecular-weight B-cell growth factor
LUMO Lowest Unoccupied Molecular Orbital
MD Molecular Dynamics
MEP Molecular Electrostatic Potential
MLP Molecular Lipophilicity Potential
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • broad based tumor
    ±âÀúºÎ°¡ ³ÐÀº Á¾¾ç
  • calcified epithelial odontogenic tumor
    ¼®È¸È­ »óÇǼº Ä¡¼º Á¾¾ç
  • carotid body tumor
    °æµ¿¸Æ ¼Òü Á¾¾ç
  • cartilaginous tumor
    ¿¬°ñ¼º Á¾¾ç
    Á¶ÀýÇÒ ¼ö ¾øÀ» Á¤µµ·Î °è¼Ó ÁøÇàµÇ´Â ¼¼Æ÷ºÐ¿­¿¡ ÀÇÇÑ ¿¬°ñ Á¶Á÷ÀÇ »õ·Î¿î Áõ½Ä ¹× Áõ´ë.
  • cavernous tumor
    ÇØ¸é»ó Á¾¾ç, ÇØ¸éÁ¾
    µ¿ÀǾî=cavenoma.
  • central giant cell tumor
    Á߽ɼº °Å´ë ¼¼Æ÷ ¾ÏÁ¾
  • cerebellopontine tumor
    ¼Ò³ú ±³°¢ Á¾¾ç
  • children tumor
    ¼Ò¾Æ ¾Ï
    ¼Ò¾Æ¿¡°Ô »ý±â´Â ¾Ç¼º Á¾¾ç. ¼Ò¾Æ¿¡°Ô´Â À§¾Ï, Æó¾Ï, Àڱà ¾Ï µîÀº °ÅÀÇ º¼ ¼ö ¾øÁö¸¸, ±Þ¼º ¹éÇ÷º´, ¾Ç¼º ¸²ÇÁÁ¾, ³úÁ¾¾ç, °íȯ žƼº ¾Ï, ½Å°æ¾Æ¼¼Æ÷Á¾, °£¾Ï, °ñ À°Á¾, ºñ·ç½º¼º Á¾¾ç µîÀÌ ¸¹´Ù.
  • congenital intracranial tumor
    ¼±Ãµ¼º µÎ°³³» Á¾¾ç
  • delta cell tumor
    µ¨Å¸ ¼¼Æ÷ Á¾¾ç
    ¼Ò¸¶Å佺ŸƾÀ» ºÐºñÇÏ´Â Á¾¾çÀ¸·Î ¼Ò¸¶Å佺ŸƾÁ¾
  • dermoid tumor
    À¯ÇÇÁ¾
  • dysembryoplastic neuroepithelial tumor
    ÀÌÇü¼º ¹è¾Æ¼º ½Å°æ»óÇÇÁ¾
    ¾à¹° Ä¡·á¿¡ ¹ÝÀÀÇÏÁö ¾ÊÀº ºÎºÐ º¹ÇÕÇü °£ÁúÀ» Ư¡ÀûÀ¸·Î µ¿¹ÝÇÏ´Â Á¾¾çÀ¸·Î¼­ 20¼¼ ¹Ì¸¸ÀÇ Ã»¼Ò³â±â¿¡ Áõ»óÀÌ ½ÃÀ۵ȴÙ. ÃøµÎ¿±¿¡ È£¹ßÇϸç ÀüµÎ¿±À̳ª µÎÁ¤¿±¿¡¼­ ¹ß»ýµÇ±âµµ ÇÑ´Ù. ´Ù°áÀý¼º Á¾±«·Î¼­ ÇÌÁö±³Á¾¼º ¼¼Æ÷µéÀÌ Á¡¾×¼º ±âÁú°ú ÇÔ²² ³ªÅ¸³­´Ù. ÀÌ·¯ÇÑ ÇÌÁö±³Á¾¼º ¼¼Æ÷µéÀº ¸é¿ªÁ¶Á÷È­ÇÐÀû ¶Ç´Â ÀüÀÚÇö¹Ì°æÀû °üÂû»ó ¼º»ó ¼¼Æ÷, ÇÌÁö±³ ¼¼Æ÷, ½Å°æ¿ø ¼¼Æ÷µéÀÌ ¼¯¿©Á® ÀÖÀ½ÀÌ Áõ¸íµÇ¾ú´Ù. ¾ç¼º Á¾¾çÀ̸ç ÁÖÀ§¿¡ ´ë³ú ÀÌÇü¼ºÁõÀ» ÈçÈ÷ µ¿¹ÝÇÑ´Ù.
  • endoaermal sinus tumor
    ³»¹è¿±µ¿ Á¾¾ç
    ¹ß»ý ºóµµ°¡ ³·Áö¸¸ ³­¼ÒÀÇ ¾Ç¼º »ý½Ä ¼¼Æ÷Á¾ Áß¿¡ µÎ ¹øÂ°·Î ÈçÇϰí Àüü ³­¼Ò Á¾¾çÀÇ 1% Á¤µµ¸¦ Â÷ÁöÇÑ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ³­È² ³¶ÀÇ ³»¹è¿± µ¿À» ´à¾Ò´Ù ÇÏ¿© ³­È² ³­ Á¾¾ç ¶Ç´Â ³»¹è¿±µ¿ Á¾¾çÀ̶ó°í ÇÑ´Ù. ÀÌ Á¾¾çÀº ÁÖ·Î ¾î¸°ÀÌ¿Í ÀþÀº ¿©¼º¿¡ È£¹ßÇÏ°í Æò±Õ ¿¬·ÉÀº 19¼¼ÀÌ´Ù. Çö¹Ì°æÀûÀ¸·Î ÀÛÀº ´Ù¹æ¼º ³¶ ±¸Á¶¸¦ °®´Â °íÇü¼º Á¾¾çÀÌ°í ´ë°³ ÀÏÃø¼ºÀÌ´Ù. ¾û¼ºÇÑ ¸Á»óÇü ¾ç»ó, Schiller-¿·¹Ì ¼Òü¸¦ Çü¼ºÇÏ´Â À¯µÎ ¾ç»ó, ´Ù¼Ò ³¶Æ÷¼º ³­È² ¾ç»ó, °íÇü¼º ¾ç»ó µîÀÌ È¥ÇÕµÇ¾î ³ª¿À°í ±¸¼º ¼¼Æ÷´Â ¹Ì¼º¼÷ ¹è ¼¼Æ÷ÀÇ Æ¯Â¡À» °®´Â´Ù. ¼¼Æ÷Áú ¾ÈÀ̳ª ¼¼Æ÷ ¹Û¿¡ À¯¸®Áú ±¸»óüµéÀÌ °üÂûµÇ´Âµ¥ À̵éÀº ¸é¿ª È¿¼Ò ¿°»ö¿¡¼­ ¾ËÆÄ ÅÂ¾Æ ´Ü¹é
  • endometrioid tumor
    Àڱà ³»¸·¾ç Á¾¾ç
  • exophytic mucosal tumor
    ¿ÜÇ⼺ Á¡¸· Á¾¾ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 4
heparin, low-molecular-weight <chemical> Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of haemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
Pharmacological action: anticoagulant, fibrinolytic agent.
(12 Dec 1998)
directed molecular evolution Techniques used to produce molecules exhibiting properties that conform to the demands of the experimenter.
(12 Dec 1998)
epidemiology, molecular The application of molecular biology to the answering of epidemiological questions. The examination of patterns of changes in DNA to implicate particular carcinogens and the use of molecular markers to predict which individuals are at highest risk for a disease are common examples.
(12 Dec 1998)
european molecular biology lab gene bank <molecular biology> A large database of DNA sequence data in Heidelberg, Germany, compiled from international sources. It is the European equivalent to the Genbank DNA sequence databank in the United States of America.
WWW: EMbase.
(09 Oct 1997)
evolution, molecular Evolution at the molecular level of DNA sequences and proteins. (rieger et al., glossary of genetics: classical and molecular, 5th ed)
(12 Dec 1998)
kinetic molecular theory <chemistry> This theory assumes that molecules must collide in order to react. The more collisions the more likely it is for a reaction to occur.
However, depending on the conditions, only a small fraction of the collisions are effective in producing a reaction. There are several constraints. In order for a reaction to occur, bonds initially are broken, which requires energy. This energy depends on the type of the reaction and comes from the kinetic energies that the molecules possess before the collision. It is called the activation energy. Increasing the temperature increases the kinetic energies and more collisions will occur. In adition, at a higher temperature a greater number of the reacting molecules might possess an energy equal to or greater than the activation energy. However the molecules must also collide in a specific orientation, called the steric factor in order for a reaction to occur.
A reaction will only be successful, if the collision has enough energy to be either equal to or greater than the activation energy and if the orientation of the collision allows for correct bond formation. These factors are in the Arrhenius equation: k = zp The rate constant k is proportional to the Arrhenius factor A. A is the product of the collision frequency z, and the steric factor p. The fraction of collisions with sufficient energy to produce a reaction are in the term of the equation.
(09 Jan 1998)
kininogen, high-molecular-weight A plasma protein, molecular weight of 110 kD, that normally exists in plasma in a 1:1 complex with prekallikrein. Hmwk is split by plasma kallikrein to produce bradykinin. The complex is a cofactor in the activation of coagulation factor xii. The product of this reaction, xiia, in turn activates prekallikrein to kallikrein.
(12 Dec 1998)
kininogen, low-molecular-weight A protein, molecular weight 50 kD, located in various normal tissues. Upon cleavage by kallikrein or other kallikreins, it forms kallidin. Kallidin, in turn, is converted into bradykinin.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á